MedTrace Logo

HYperfractionated Radiation Therapy Versus Concurrent Chemoradiation for Head and Neck Cancer (HYTC)

NCT07801235 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 604

Last updated 2026-09-03

No results posted yet for this study

Summary

This is an international multi-centre, non-inferiority phase III randomized controlled trial comparing concurrent chemoradiation with high dose cisplatin (Arm A) vs. hyperfractionated radiation therapy (Arm B) in patients with head and neck squamous cell carcinoma.

Conditions

  • Head and Neck (HNSCC)

Interventions

RADIATION

70 gy 35 fractions/7weeks+high dose of cisplatin

70 Gy 35 fractions/7weeks+high dose of cisplatin

RADIATION

81.6 Gy /68 fractions BID FOR 7 WEEKS

81.6 Gy /68 fractions BID FOR 7 WEEKS

Sponsors & Collaborators

  • Princess Margaret Hospital, Canada

    collaborator OTHER

  • King Hussein Cancer Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-20
Primary Completion
2033-04-01
Completion
2033-04-01

Countries

  • Jordan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07801235 on ClinicalTrials.gov